SCHEDULE: Vanguard Group Exits Pacira BioSciences Stake

The Vanguard Group reported 0% beneficial ownership in Pacira BioSciences Inc. following an internal realignment.

Summary

• The Vanguard Group filed an Amendment No. 12 to its Schedule 13G for Pacira BioSciences Inc.
• As of March 13, 2026, The Vanguard Group reported 0 shares beneficially owned, representing 0% of Pacira BioSciences Inc.'s Common Stock.
• This change is a result of an internal realignment within The Vanguard Group, Inc. on January 12, 2026.
• Following the realignment, certain subsidiaries or business divisions of The Vanguard Group, Inc. will now report beneficial ownership separately (on a disaggregated basis).
• The Vanguard Group, Inc. no longer has, or is deemed to have, beneficial ownership over securities beneficially owned by these subsidiaries and/or business divisions.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this filing as neutral. It reflects an administrative change in how The Vanguard Group reports its holdings, not a positive or negative investment decision regarding Pacira BioSciences Inc.

Industry Context

StockSavvy.ai notes that Schedule 13G filings primarily serve as a transparency mechanism for large institutional investors. This specific amendment reflects an internal operational change within The Vanguard Group rather than a strategic divestment from Pacira BioSciences Inc. The disaggregation of reporting by Vanguard's subsidiaries is a procedural adjustment, not an investment decision related to Pacira's performance or outlook.

Stakeholder Impact

• Shareholders of Pacira BioSciences Inc. should be aware that The Vanguard Group, Inc. itself no longer directly reports beneficial ownership, but its subsidiaries may still hold shares, impacting the overall institutional ownership landscape.

Key Dates

Recommendation

The filing details an administrative change in The Vanguard Group's reporting structure, resulting in 0% direct beneficial ownership reported by the parent entity. This does not reflect a change in investment thesis for Pacira BioSciences Inc. or a divestment of underlying holdings by Vanguard's broader family of funds, which will now report separately. Therefore, a 'hold' recommendation is appropriate as this filing provides no new fundamental information to alter an existing investment stance.

Keywords

Pacira BioSciences, Vanguard Group, Schedule 13G, Beneficial Ownership, Common Stock, Institutional Investor